دورية أكاديمية
أعرض في EDS

IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications.

التفاصيل البيبلوغرافية
العنوان: IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications.
المؤلفون: Nguyen V; The Brain Tumor Center of Excellence, Departments of Neurosurgery, Wake Forest University Health Sciences Comprehensive Cancer Center, Winston-Salem, NC, USA., Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A
المصدر: Translational oncology [Transl Oncol] 2011 Dec; Vol. 4 (6), pp. 390-400. Date of Electronic Publication: 2011 Dec 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-5233 (Electronic) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Ann Arbor, MI] : Neoplasia Press
مستخلص: Glioblastoma multiforme (GBM) overexpresses interleukin 13 receptor α2 (IL-13Rα2), a tumor-restricted receptor that is not present in normal brain. We and others have created targeted therapies that specifically eradicate tumors expressing this promising tumor-restricted biomarker. As these therapies head toward clinical implementation, it is critical to explore mechanisms of potential resistance. We therefore used a potent IL-13Rα2-targeted bacterial cytotoxin to select for naturally occurring "escapee" cells from three different IL-13Rα2-expressing GBM cell lines. We found that these side populations of escapee cells had significantly decreased IL-13Rα2 expression. We examined clinically relevant biologic characteristics of escapee cell lines compared to their parental cell lines and found that they had similar proliferation rates and equal sensitivity to temozolomide and radiation, the standard therapies given to GBM patients. In contrast, our escapee cell lines were less likely to form colonies in culture and migrated more slowly in wound healing assays. Furthermore, we found that escapee cells formed significantly less neurospheres in vitro, suggesting that IL-13Rα2-targeted therapy preferentially targeted the "stem-like" cell population and possibly indicating decreased tumorigenicity in vivo. We therefore tested escapee cells for in vivo tumorigenicity and found that they were significantly less tumorigenic in both subcutaneous and intracranial mouse models compared to matching parental cells. These data, for the first time, establish and characterize the clinically relevant biologic properties of IL-13Rα2-targeted therapy escapees and suggest that these cells may have less malignant characteristics than parental tumors.
References: Int J Cancer. 1998 May 18;76(4):547-51. (PMID: 9590132)
Cancer Res. 2004 Dec 15;64(24):9160-6. (PMID: 15604287)
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6. (PMID: 21030678)
Cancer Res. 2007 Sep 1;67(17):7983-6. (PMID: 17804706)
Neuro Oncol. 2010 Aug;12(8):871-81. (PMID: 20511192)
Neurol Clin. 2007 Nov;25(4):1111-39, x. (PMID: 17964028)
Expert Rev Neurother. 2009 Oct;9(10):1519-27. (PMID: 19831841)
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15124-9. (PMID: 12417744)
Cancer Biother Radiopharm. 2008 Oct;23(5):581-9. (PMID: 18976118)
Mol Med. 2000 May;6(5):440-9. (PMID: 10952023)
J Clin Oncol. 2007 Mar 1;25(7):837-44. (PMID: 17327604)
Neurosurg Focus. 2006 Apr 15;20(4):E15. (PMID: 16709020)
Technol Cancer Res Treat. 2006 Jun;5(3):239-50. (PMID: 16700620)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5. (PMID: 11121071)
Clin Cancer Res. 2008 Jan 1;14(1):199-208. (PMID: 18172271)
Neurosurgery. 2007 Nov;61(5):1031-7; discussion 1037-8. (PMID: 18091279)
Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):87-98. (PMID: 11418305)
J Neurosurg. 2010 Aug;113(2):301-9. (PMID: 20020841)
Cancer Invest. 2002;20(5-6):801-9. (PMID: 12197239)
Neurology. 2009 Oct 13;73(15):1200-6. (PMID: 19822869)
J Neurooncol. 2003 Aug-Sep;64(1-2):117-23. (PMID: 12952292)
AJR Am J Roentgenol. 2007 Mar;188(3):703-9. (PMID: 17312057)
Int J Oncol. 1999 Sep;15(3):481-6. (PMID: 10427128)
Cancer Biol Ther. 2007 Mar;6(3):432-8. (PMID: 17312388)
Clin Cancer Res. 1999 May;5(5):985-90. (PMID: 10353730)
Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895)
Nat Biotechnol. 1998 May;16(5):449-53. (PMID: 9592393)
J Neurosurg. 1998 Jan;88(1):1-10. (PMID: 9420066)
Mol Ther. 2010 Feb;18(2):377-85. (PMID: 19904233)
J Biol Chem. 1995 Jul 14;270(28):16775-80. (PMID: 7622490)
Cancer Gene Ther. 2005 Mar;12(3):228-37. (PMID: 15550937)
Mol Cancer Ther. 2006 Dec;5(12):3162-9. (PMID: 17172420)
Stem Cells. 2006 Dec;24(12):2851-7. (PMID: 16945995)
Stem Cells. 2009 Aug;27(8):1734-40. (PMID: 19536809)
Breast J. 2010 May-Jun;16(3):309-12. (PMID: 20408821)
Clin Cancer Res. 1995 Nov;1(11):1253-8. (PMID: 9815919)
Neoplasia. 2002 Sep-Oct;4(5):388-99. (PMID: 12192597)
Tumour Biol. 2006;27(6):309-18. (PMID: 17033200)
J Neurooncol. 2000 Jun;48(2):103-11. (PMID: 11083073)
Methods Mol Biol. 2009;568:73-83. (PMID: 19582422)
معلومات مُعتمدة: K08 NS076548 United States NS NINDS NIH HHS; R01 CA181429 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20111223 Date Completed: 20121002 Latest Revision: 20211021
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3243662
DOI: 10.1593/tlo.11175
PMID: 22191003
قاعدة البيانات: MEDLINE
الوصف
تدمد:1936-5233
DOI:10.1593/tlo.11175